Patricia Inácio, PhD, science writer —

Soliris (eculizumab) appears to be more effective in atypical hemolytic uremic syndrome (aHUS) patients with complement abnormalities, than in those whose disease was triggered by other underlying conditions, a 20-year retrospective analysis has found. The risk of disease relapse over the course of five years was 40% higher…

Soliris (eculizumab) and hemodialysis improved kidney function in a man with end-stage kidney disease who was diagnosed with atypical hemolytic uremic syndrome (aHUS) after a kidney transplant, according to a case study from South Korea. The report “emphasizes the importance of primary kidney disease evaluation and careful monitoring”…

The case of a 69-year-old-woman with atypical hemolytic uremic syndrome (aHUS) who carried mutations in the CFI and the DGKE genes that hadn’t previously been associated with the disease, was described in a recent report. The woman responded well to treatment with…

An 11-year-old boy was diagnosed with atypical hemolytic uremic syndrome (aHUS) after having symptoms that included a hard-to-treat headache, low appetite, fever, and shortness of breath, according to a case report from Nepal. His symptoms underscore the need for a “multidisciplinary approach … for aHUS due to its rarity…

A teenager with a mutation in the C3 gene developed atypical hemolytic uremic syndrome (aHUS), which manifested as bleeding in the lungs, after undergoing kidney transplant surgery. According to clinicians, a correct and timely diagnosis in a case like this is essential for improving treatment outcomes. “In patients presenting…

A delay in diagnosing and treating a woman with pregnancy-related atypical hemolytic uremic syndrome (aHUS) may have contributed to her kidney failure, a U.S. case study suggests. Her condition was first thought to be thrombotic thrombocytopenic purpura (TTP), a related blood disorder. Until she was finally diagnosed correctly…

Intensive treatment with anti-vascular endothelial growth factor (anti-VEGF) medications — commonly used to treat disorders causing vision impairments — are thought to have led to the onset of atypical hemolytic uremic syndrome (aHUS) in a man in his 40s. It is a rare finding in an extremely rare disease,…

Mutations in the THBD gene — previously suggested to predispose people to atypical hemolytic uremic syndrome (aHUS) — might not make any significant contribution to the disease’s development and its severity, according to a small Spanish study. The mutations were found in Spanish aHUS patients at similar frequencies to…

Soliris (eculizumab) was effective in enhancing kidney disease-free survival in patients with atypical hemolytic uremic syndrome (aHUS), a real-world study reported. Specifically, data showed Soliris was able to increase patients’ five-year survival rate without signs of kidney disease by nearly five times. According to authors, this was the…

Pregnancy was identified as the trigger event for atypical hemolytic uremic syndrome (aHUS) that resulted in kidney damage for a genetically predisposed woman in her mid-20s, a U.S. case study reported. The patient had a clinical history of poorly managed high blood pressure and often failed to comply with…